hcp

Introducing the NexConnect Patient Support Program

NexConnect surrounds patients with support and will brings them additional information to complement their doctor-recommended Nexavar treatment

Learn more Enroll online

Insurance Coverage & Assistance

The REACH (Resources for Expert Assistance and Care Helpline) Program provides help with understanding insurance coverage and finding other programs to financially assist patients receiving Nexavar.

Learn more Enrollment Form

Nexavar Medical Information

This medical information site provides access for health care providers to product information, congress presentations and posters, clinical trial information, and bibliography information for Nexavar.

Visit NexavarMedicalInformation.com

- + Text Zoom

The First and Only Treatment Proven to Significantly Improve Overall Survival in Patients with Unresectable Hepatocellular Carcinoma (HCC)

Nexavar was the first targeted therapy

 
targeted therapy
A type of medicine that affects specific parts of cancer cells.
indicated for the treatment of patients with advanced renal cell carcinoma (RCC). Now, Nexavar is the first and only systemic treatment proven to extend survival in patients with unresectable HCC.

A First in Unresectable HCC Increased overall survival in patients with unresectable HCC by 44%* (median: 10.7 months with Nexavar vs 7.9 months with placebo; P=.00058; HR, 0.69; 95% CI, 0.55-0.87)Learn more A First in Advanced RCC Doubled progression-free survival in advanced RCC (median: 24 weeks with Nexavar vs 12 weeks with placebo; P<.000001; HR, 0.44; 95% CI, 0.35-0.55)Learn more
*Formula: (1.0/HR-1) X 100%.

A unique mechanism of action

Learn how Nexavar works along multiple signaling pathways to block cell proliferation and tumor angiogenesis in HCC.


View mechanism of action

A new path to HCC knowledge

RAFscience.com is an educational resource for medical professionals interested in learning more about the role of the RAF kinase cell-signaling pathway in hepatocellular carcinoma (HCC).


Visit RAFscience.com